Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex’s proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.
Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex’s proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Thinking about Cord Blood Banking? Expect these answers to your QuestionsNavya_Sharma
Since going for cord blood blanking is an important decision and something that concerns your baby’s future and wellbeing, it is natural to have many questions. As parents before you zero down on the cord blood banking company whom you will entrust to secure your babies precious stem cells for more than two decades of his life. visit, https://www.cordlifeindia.com/
Cystic Fibrosis Drug Development Solutions Covance
Succeed in cystic fibrosis studies with an experienced and trusted partner CF remains one of the most common life-shortening inherited diseases, despite breakthroughs in targeted therapies in recent years. Research and development efforts continue, but those involved face major challenges in finding specialized trials sites and enrolling sufficient numbers of eligible patients.
Canada is a hotbed for the commercialization of regenerative medicine and stem cell discoveries. How appropriate, since two Canadian doctors, James Till and Ernest McCulloch discovered transplantable stem cells at the Ontario Cancer Institute in Toronto in 1961.
Accelerated growth in this industry sector is opening up new job opportunities for medical laboratory technologists. The benefits include working with scientific discoveries and leading-edge technologies to find exciting new treatment options that can help people living with devastating diseases and conditions.
Check out my story From Bench to Business in the Winter 2015 issue of the Canadian Journal of Medical Laboratory Science. I enjoyed interviewing Lianne Witt, technical director of laboratory and client services at Insception Lifebank, Canada’s largest private cord blood bank, and Emily Titus, manager of technology at Centre for Commercialization for Regenerative Medicine (CCRM). Their career paths are inspiring for medical laboratory technologists looking for opportunities beyond traditional hospital labs. It is a great time to be working in the fields of regenerative medicine and stem cells!
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
Oncology is one of the most research-intensive therapeutic areas, yet no two development programs are the same. No two trials are the same. Each one calls for a customized strategy and distinct trial management approach. Covance develops fit-for-purpose solutions Designed Around You® that enable more efficient clinical trials and focus on what is most valuable to your organization.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
BioPharma Medical Affairs Congress, West Coast WorldCongress
Medical Affairs teams face persistent challenges to be the interface between their company, product, KOL external experts, and prescribers. Evolving restrictions for compliance and limited commercial resources have placed greater emphasis onto Medical Affairs teams. BioPharma has greatly restricted resources and must rely greatly on these teams to communicate medical information and promote value. This summit focuses on strategies for engagement and success for medical affairs organizations to meet current and future organization needs.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Thinking about Cord Blood Banking? Expect these answers to your QuestionsNavya_Sharma
Since going for cord blood blanking is an important decision and something that concerns your baby’s future and wellbeing, it is natural to have many questions. As parents before you zero down on the cord blood banking company whom you will entrust to secure your babies precious stem cells for more than two decades of his life. visit, https://www.cordlifeindia.com/
Cystic Fibrosis Drug Development Solutions Covance
Succeed in cystic fibrosis studies with an experienced and trusted partner CF remains one of the most common life-shortening inherited diseases, despite breakthroughs in targeted therapies in recent years. Research and development efforts continue, but those involved face major challenges in finding specialized trials sites and enrolling sufficient numbers of eligible patients.
Canada is a hotbed for the commercialization of regenerative medicine and stem cell discoveries. How appropriate, since two Canadian doctors, James Till and Ernest McCulloch discovered transplantable stem cells at the Ontario Cancer Institute in Toronto in 1961.
Accelerated growth in this industry sector is opening up new job opportunities for medical laboratory technologists. The benefits include working with scientific discoveries and leading-edge technologies to find exciting new treatment options that can help people living with devastating diseases and conditions.
Check out my story From Bench to Business in the Winter 2015 issue of the Canadian Journal of Medical Laboratory Science. I enjoyed interviewing Lianne Witt, technical director of laboratory and client services at Insception Lifebank, Canada’s largest private cord blood bank, and Emily Titus, manager of technology at Centre for Commercialization for Regenerative Medicine (CCRM). Their career paths are inspiring for medical laboratory technologists looking for opportunities beyond traditional hospital labs. It is a great time to be working in the fields of regenerative medicine and stem cells!
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
Oncology is one of the most research-intensive therapeutic areas, yet no two development programs are the same. No two trials are the same. Each one calls for a customized strategy and distinct trial management approach. Covance develops fit-for-purpose solutions Designed Around You® that enable more efficient clinical trials and focus on what is most valuable to your organization.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
BioPharma Medical Affairs Congress, West Coast WorldCongress
Medical Affairs teams face persistent challenges to be the interface between their company, product, KOL external experts, and prescribers. Evolving restrictions for compliance and limited commercial resources have placed greater emphasis onto Medical Affairs teams. BioPharma has greatly restricted resources and must rely greatly on these teams to communicate medical information and promote value. This summit focuses on strategies for engagement and success for medical affairs organizations to meet current and future organization needs.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
The key differences between the MDR and IVDR in the EUAllensmith572606
In the European Union (EU), two significant regulations have been introduced to enhance the safety and effectiveness of medical devices – the In Vitro Diagnostic Regulation (IVDR) and the Medical Device Regulation (MDR).
https://mavenprofserv.com/comparison-and-highlighting-of-the-key-differences-between-the-mdr-and-ivdr-in-the-eu/
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
2. 2
A Comprehensive Approach
Cord Blood
Stem Cell
Banking
Private Adult Stem
Cell Banking
Public Banking
Cellular
Therapy
Biological Safety Deposit Box
CONFIDENTIAL
FDA
Changing the Model
Cord Blood Banking
3. 3
Pillars of the Business
3 Divisions
FDA drug license
Cord Blood Banking Adult Banking Public Banking
20 years but still “new” to consumers 1st in class
Multibillion dollar market CU partnerships and collaborations
Strong recurring revenues
Possible exclusivity
National programHigh profit potential
CONFIDENTIAL
4. 4
High Potential
Public, Private, and Research
Private Banking Adult Banking
• Twenty years of use and
technical ability
• Multi-billion dollar
consumer business in
place and maturing
• Dominated by marketing
companies
• Strong recurring
revenues
• Opportunity to take
share
• New product
• Market introduction
• High end target
market
• Collections through
blood centers
nationwide
Public
• FDA drug license
• Regenerative
medicine research
• Leverage university
assets
CONFIDENTIAL
5. 5
• 32 acre medical campus
• 6.4 million square feet
• 7,000+ faculty members
• 21,000+ employees
• Serving over 500,000 patients annually
• Established in 1883
University of Colorado
The Medical Campus
CONFIDENTIAL
6. 6
Part of an Integrated Medical Center
The University of Colorado
School of Medicine
Bioengineering and Applied
Science
Bioscience Park
University of Colorado
Hospital
Gates Center for Regenerative
Medicine
Children’s Hospital Colorado
At the University of Colorado
CONFIDENTIAL
Anschutz Medical Campus
7. 7
• Administered by transplant physicians and histocompatibility scientists committed to
improving patient transplant outcomes
• Collecting and banking umbilical cord blood since 1996; accredited by the AABB
• Class 10,000 cGMP stem cell processing facility
• HRSA Contractor for National Cord Blood Inventory (NCBI) since 2006
• Cord blood units are available through the NMDP
• Confirmatory HLA typing
• More than 750 units released for patient transplants
• Units shipped to more than 120 transplant programs in Argentina, Australia, Belgium,
Brazil, Canada, China, France, Italy, Mexico, New Zealand, Spain, United Kingdom, Uruguay,
and the United States
• 50% of units are from minority donors
• FDA License No. 1855, received on May 24th, 2012
Public Cord Blood Banking
Processing Cord Blood Units
under License for 3 Years
Processing Donated Cord Blood
Units for 18 Years
Inventory of 10,000+
Cord Blood Units
FDA License No. 1855, Received May 24th, 2012
CONFIDENTIAL
8. 8
ClinImmuneLabs
At the University Of Colorado
CONFIDENTIAL
Dr. Brian Freed
Executive Director and
Professor at the
University of Colorado’s
School of Medicine
Sharon Miller,
CHS MT
Director of
Regulatory
Affairs
Regulatory
Michael
Aubrey, MS
Chief
Operating
Officer
Operations
Tate
Hermanson
Director of
Business
Services
Administration
Dr. Ralph Quinones
Director of Blood
and Marrow
Processing
Laboratory
Co-Medical Director
Dr. Jonathan
Gutman
Clinical Director
of Allogeneic
Transplantation
Co-Medical Director
Executive Director
9. 9
ClinImmune is Comprised of Six Laboratories
These laboratories provide services to kidney, heart, lung, pancreas, and hematopoietic stem cell
transplant programs including: University of Colorado Hospital, Colorado Children’s Hospital,
Presbyterian/St. Luke’s (Denver, Colorado), Northside Hospital (Atlanta, Georgia), and St. Francis
Hospital (Charleston, South Carolina).
Providing Services to Hospitals Nationwide
Histocompatibility
Clinical Immunology
Flow Cytometry
CariCord
Human Stem Cell Processing
Public Cord Blood Bank is FDA Licensed
18 years
Expertise and Experience
CONFIDENTIAL
10. 10
New Laboratory Opened 2015
CONFIDENTIAL
Largest Medical School Construction Project in the US
At the University of Colorado
In 2013, the University of Colorado Board of Regents approved a new Bioscience 2
facility which will contain our state of the art Class 10,000 cGMP lab. The University
celebrated with a Grand Opening Ceremony on 11/18 2015. The District’s adjacency to
the Anschutz Medical Campus and its formal affiliation with the University of Colorado
provides priority access and support for research and product development.
11. 11
• CariCord is a stem cell services company providing best in class cord blood and tissue preservation,
focused on improving the health, wellness and quality of life of families who choose to save their
baby’s stem cells at birth.
• A component of ClinImmune Labs at the University of Colorado, CariCord combines the latest
scientific research with ongoing feedback from both transplant physicians and the research
community to maintain its cutting edge quality standards within the newborn stem cell storage
market.
• 2014, CariCord launched our initial sales efforts to both the OBGYNs, utilizing an experienced
management team and concurrently direct to consumers, via advertising and a call center with sales
agents. We have seen rapid acceptance of our offering and core messages: Stability, Quality and
Experience.
• 2015, we have built a scalable model and are seeking investment partners to facilitate rapid growth,
as we fuel our market launch and upwards growth trajectory.
About CariCord
A Unique Model with a Strong Message
CONFIDENTIAL
12. 12
ExperiencedLeadershipTeam
Over 50 Combined Years of Cord Blood Industry Knowledge
Calvin Cole
President &
CEO
President
Brian
McEnroe
Sr. VP Sales
& Marketing
Sales and Marketing
Ranelle
Erickson
VP of
Marketing
Marketing
John Gabriel
Sr. VP
Operations
Operations
Dub Sitton
VP
of Sales
Sales
Jim Todd
Chief
Financial
Officer
Finance Global Medical Director
Ratan
Bhardwaj
MD, PhD,
Pediatric
Neurosurgery
Medical Director
Donald
Vliegenthart
MD, Board
Certified
Orthopedic
Surgeon
Scientific
Harry Kloor
PhD, PhD
Chief
Scientific
Officer
CONFIDENTIAL
14. 14
We have been processing cord blood units under federal contract since 2006.
We were among the first to elevate our cord blood banking practices to FDA BLA
licensure. I’m pleased to announce we are the first to leverage our lab’s best
practices to serve private consumers, while sustaining our efforts to build the
National Cord Blood Inventory with life-saving transplant ready units. We believe
our partnership in CariCord demonstrates a sustainable pathway that is responsive
to current and future private and federal sector demands.
“
”
Brian Freed
Executive Director of ClinImmune
Labs and Professor at the University
of Colorado’s School of Medicine
Quality Banking
History of Expertise Now Available to Families
CONFIDENTIAL
15. 15
Cord Blood Banking
Families can choose to preserve their baby’s cord blood at the time of birth, utilizing our temperature
controlled collection kit. Cord blood is currently used to treat over 80 diseases with many more in
research.
Cord Tissue Banking
Families can also choose to save their baby's cord tissue at delivery, using the CariCord collection kit cup,
always available inside our kit. Cord tissue stem cells show promising therapeutic potential in pre-clinical
research for diseases such as stroke, diabetes, Parkinson’s disease, ligament repair in sports injuries, liver
and lung repair and wound healing.
Product Pipeline
Adult Stem Cell Banking is currently under development
and details of the project are confidential at this time.
The project will have broad appeal and will save quality
stem cells, for those who enroll. Announcements regarding
the details are dependent on harvesting, processing and
storage and will be coming in the next 90 -180 days,
if not sooner.
Our Products
Current Offerings
CONFIDENTIAL
16. 16
CariCord’s goal is to become the # 1 cord blood and tissue company recommended by health care providers, to all
patients. We also plan to develop a comprehensive line of stem cell storage options for adult stem cells from
alternative sources. Key elements of the CariCord’s strategy to achieve this goal are as follows:
Our GrowthStrategy
Positioned for Success
Building the National Cord Blood Supply
We plan to combine the private and public cord blood banks and increase the number of donation
hospitals, with a goal of creating large volume, FDA licensed cord blood units, to provide to families and
healthcare professionals seeking lifesaving units for transplant.
Focus on Research
We plan to expand our efforts on research, clinical trials, and commercialization of stem cell related products.
Therapies that improve the quality of life, recovery, and outcomes for diseases treated with stem cells, will
increase the demand for stem cell storage and therapeutic treatment options for patients.
Exclusive Current Market Focus
Initially, we plan to focus exclusively on cord blood and tissue banking, focusing on superior
quality and long term stability, demonstrating to physicians that they can be confident
recommending CariCord to patients and families.
CONFIDENTIAL
17. 17
Class 10,000 clean rooms
Laboratory capacity
Oversight and management
CLINICAL
TRIALS
ClinicalTrialCenter– Researchand Development
Advancing Stem Cell Science
CONFIDENTIAL
COLLABORATION
PATH TO NEW
TREATMENTS
Dedicated partner
Researchers
Academic medical center
Commercialization
Testing for safety and efficacy
Creation of novel cellular products
18. 18
Crag T. Jordan, MD
Dr. Jordan serves as the Chief of the Hematology Division and directs a research program focused on the
development of novel therapies for the treatment of leukemia.
Brian M. Freed, PhD, DABHI
Dr. Freed is Executive Director of ClinImmune Labs and a Professor of Medicine and Immunology. ClinImmune Labs consists of
the Histocompatibility Lab, the Stem Cell Lab, the University of Colorado Cord Blood Bank, the Flow Cytometry Lab and
CariCord. His research focuses on the role of individual HLA amino acid residues in antigen presentation with the goal of
providing HLA-specific immunotherapy.
Johnathan Gutman, MD
Dr. Gutman directs the Allogeneic Bone Barrow Transplant (BMT) program and is a leading expert in the use of
umbilical cord blood derived stem cells for BMT. He oversees a broad range of clinical programs and trials.
Clay Smith, MD
Dr. Smith is the Associate Chief of Hematology and the Clinical Director for the Blood Cancer Program. He is a
highly experienced laboratory researcher and directs a program focused on the development of new therapeutic
regimens in the treatment of hematologic malignancies.
Jill Slansky, PhD
Using an animal model for colon cancer, Dr. Slansky is determining what substitutions in tumor antigen peptides can
be used to improve antitumor immunity. These so-called mimotope peptides (mimics of epitopes) activate T cells
that respond to the tumor more effectively than the natural tumor antigen.
Ross Kedl, PhD
Dr. Kedl is interested in this curious boundary between the innate and adaptive immune systems and seeks to
elucidate signals and pathways emanating from the various families of innate receptors most efficiently mediate the
transition to the adaptive cellular immune response.
Cellular Therapy Team
CONFIDENTIAL
19. 19
Mesenchymal Stem Cells Could Hold the Key to the Future of Ground Breaking Research
There are many areas of preclinical research4,5,6,7,8,9
Sports
Injuries
Lung Disease
Stroke
Liver Repair
Rheumatoid
Arthritis
Parkinson’s
Disease
Type 1
Diabetes
Burn Victims
Extensive Pipeline of Future Stem Cell Applications
Osteoarthritis
More Diseases in Research with Stem Cells
CONFIDENTIAL
21. 21
1.Moise K Jr. Umbilical Cord Stem Cells, Obstetrics Gynecology, 2005; 106(6):1393-1407 2.Nietfield JJ, Pasquini MC, Logan BR, Verter,
Horowitz MM. Lifetime Probabilities of a Hematopietic Stem Cell Transplantation in the US, Biology Blood and Marrow Transplant, 2008;
14:316-322. 3. Based on a 6/6 HLA match. 4. Stroke: Ding DC, Shyu WC, Chiang MF et al. Enhancement of Neuroplasticity through
Upregulation of B1-integrin in Human Umbilical Cord Derived Stromal Stem Cell Implanted Stroke Model, Neurobiology Dis. 2007;
27(3):339-353. E-publication 2007 June 18. 5. Parkinson’s Disease: Fu YS, Cheng YC, Lin MY, et al. Conversion of Human Umbilical Cord
Mesenchymal Stem Cells in Wharton’s Jelly To Dopaminergic Neurons in Vitro: Potential Therapeutic Application For Parkinson’s Disease,
Stem Cells. 2006; 24(1):115-124. E-publication 2005 August. 6.Rheumatoid Arthritis: Liu Y Mu R Wang S et al. Therapeutic Potential of
Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis, Arthritis Res Ther. 2010; 12(6):R210 7. Sports
Injuries (cartilage): Wang L. Tran 1, Seshareddy K et al. A Comparison of Human Bone Marrow-Derived Mesenchymal Stem Cells and
Human Umbilical Cord Derived Mesenchymal Stromal Cells for Cartilage Tissue Engineering, Tissue Eng. 2009; 15(8)(pt A): 2259-2266.
8.Type 1 Diabetes: Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells
Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type
1 Diabetes. Stem Cell Rev. October 23, 2010 E-publication. 9. Lung Cancer: Maurya DK, Doi C, Kawabata A, et al. Therapy With Un-
engineered Naïve Rat Umbilical Cord Blood Matrix Stem Cells Markedly Inhibits Growth of Murine Lung Adenocarcinoma, BMC Cancer,
2010;10-590. 10. Data on file as of February 2014. 11. Accreditations current as of February 2014. 12.Center for Biologics Evaluation and
Research, Food and Drug Administration, US Department of Human and Health Services, Guidance for the Industry: Minimally
Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoetic Reconstitution for Specified Indications,
October 2009. 13. Data on file for CariCord and numbers from company websites ViaCord (268) and CBR (262) as of February 2014. 14.
Discount applies when cord blood and cord tissue banking are chosen with a prepaid storage plan. Prices effective as of February 2014
General Disclaimer: Most of the diseases currently treated with cord blood stem cells are genetic diseases. Banking cord blood does not
guarantee that your physicians will choose it as first line course of treatment over a sibling donor or autologous donor depending on the
diseases being treated and other factors in consideration of a transplant. Only a treating physician can determine when it should be used
on a case by case basis. Cord tissue research is pre-clinical and may have potential in the future but is not used in treatments in humans
currently.
CONFIDENTIAL